156,750 BioNTech SE Sponsored ADR $BNTX Shares Sold by CenterBook Partners LP

CenterBook Partners LP lessened its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 62.4% in the third quarter, according to its most recent filing with the SEC. The firm owned 94,333 shares of the company’s stock after selling 156,750 shares during the quarter. CenterBook Partners LP’s holdings in BioNTech were worth $9,273,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of BNTX. Integrated Wealth Concepts LLC acquired a new stake in BioNTech in the second quarter worth about $39,000. Farther Finance Advisors LLC raised its stake in shares of BioNTech by 31.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 493 shares of the company’s stock worth $48,000 after buying an additional 118 shares in the last quarter. Quintet Private Bank Europe S.A. raised its stake in shares of BioNTech by 232.8% in the 3rd quarter. Quintet Private Bank Europe S.A. now owns 1,917 shares of the company’s stock worth $188,000 after buying an additional 1,341 shares in the last quarter. Quantum Portfolio Management LLC acquired a new stake in shares of BioNTech in the first quarter valued at $203,000. Finally, Vise Technologies Inc. acquired a new stake in shares of BioNTech in the third quarter valued at $228,000. Institutional investors own 15.52% of the company’s stock.

Insider Buying and Selling at BioNTech

In other news, CEO Ugur Sahin sold 72,000 shares of the business’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $97.23, for a total transaction of $7,000,560.00. Following the sale, the chief executive officer owned 108,209 shares in the company, valued at $10,521,161.07. The trade was a 39.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 807,209 shares of company stock valued at $79,246,837 over the last quarter. Company insiders own 19.20% of the company’s stock.

BioNTech Trading Up 1.9%

Shares of NASDAQ:BNTX traded up $1.65 during midday trading on Friday, reaching $87.51. The company had a trading volume of 724,157 shares, compared to its average volume of 1,124,157. The company has a fifty day simple moving average of $94.66 and a two-hundred day simple moving average of $96.70. The firm has a market cap of $22.13 billion, a price-to-earnings ratio of -12.78 and a beta of 1.28. BioNTech SE Sponsored ADR has a 1-year low of $79.52 and a 1-year high of $124.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%. The company had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. During the same quarter in the previous year, the firm posted ($1.60) EPS. BioNTech’s quarterly revenue was down 59.5% on a year-over-year basis. Research analysts predict that BioNTech SE Sponsored ADR will post -6.38 earnings per share for the current year.

Analysts Set New Price Targets

BNTX has been the topic of a number of research analyst reports. Bank of America reaffirmed a “buy” rating on shares of BioNTech in a report on Wednesday. Canaccord Genuity Group reduced their price objective on shares of BioNTech from $136.00 to $132.00 and set a “buy” rating for the company in a research report on Wednesday, October 14th. Argus assumed coverage on shares of BioNTech in a research note on Thursday, October 8th. They issued a “hold” rating on the stock. Morgan Stanley dropped their target price on shares of BioNTech from $114.00 to $106.00 and set an “overweight” rating on the stock in a report on Wednesday. Finally, Berenberg Bank set a $140.00 target price on shares of BioNTech in a research note on Wednesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $123.60.

BioNTech Company Profile

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing medicines and vaccines based on messenger RNA and other immunotherapy technologies. The company’s research programs address cancer, infectious diseases, and other serious medical conditions.

BioNTech’s oncology portfolio includes individualized and off-the-shelf cancer immunotherapies, including mRNA-based treatments, cell therapies, antibody-based therapies, and immune-modulating approaches. Its infectious-disease activities include vaccine programs developed through proprietary platforms and collaborations.

In collaboration with Pfizer, BioNTech developed Comirnaty, an mRNA-based COVID-19 vaccine.